Traders Purchase Large Volume of Compass Pathways Call Options (NASDAQ:CMPS)

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) saw some unusual options trading activity on Monday. Investors bought 5,436 call options on the company. This is an increase of 77% compared to the average volume of 3,069 call options.

Key Headlines Impacting Compass Pathways

Here are the key news stories impacting Compass Pathways this week:

• Positive Sentiment: White House executive order to accelerate psychedelics research and access — reduces regulatory timeline risk and prompted renewed investor interest in psilocybin developers like Compass. How Trump’s psychedelics executive order could unlock stalled cannabis reform
• Positive Sentiment: Clinical/FDA momentum: recent press coverage highlights Compass’s Phase 3 wins and filing momentum for its COMP360 psilocybin program, supporting a clearer path toward regulatory filings. Why COMPASS Pathways (CMPS) Is Up 15.4% After Psilocybin Phase 3 Wins And FDA Filing Momentum
• Positive Sentiment: Short‑squeeze/market dynamics amplified the rally — analysts and commentary note high short interest in the name, which accelerated buying after the policy news. This 4/20, Wall Street Is Betting on More Than Marijuana
• Positive Sentiment: Broker support: BTIG reaffirmed a buy rating with a $14 price target (noted coverage via Benzinga), giving an analyst upside narrative for the stock. Benzinga report on BTIG rating
• Positive Sentiment: Unusually large options activity — a spike in call buying (5,436 calls, ~77% above typical volume) signals speculative positioning and conviction by traders ahead of further catalysts.
• Neutral Sentiment: Investor outreach/visibility: CEO Kabir Nath will speak at the Needham Virtual Psychedelics Forum (April 27), offering additional investor updates and program clarity. Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 2026
• Neutral Sentiment: Broader media coverage (Bloomberg, CNN, MSN) is amplifying the story and drawing retail/institutional attention, which can sustain higher intraday volume. Stock Movers: Eli Lilly, Compass Pathways, Fermi
• Negative Sentiment: Fundamental risks remain — Compass reported an earnings miss in March and is a pre‑revenue, cash‑burning biotech with negative EPS; ultimate value depends on regulatory approvals, successful commercialization and execution. (Keep an eye on dilution risk and future financing needs.)

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Persistent Asset Partners Ltd acquired a new position in shares of Compass Pathways in the 4th quarter valued at $38,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Compass Pathways in the 4th quarter valued at $47,000. Advisory Services Network LLC acquired a new position in shares of Compass Pathways in the 3rd quarter valued at $41,000. BIT Capital GmbH acquired a new position in shares of Compass Pathways in the 3rd quarter valued at $54,000. Finally, MML Investors Services LLC acquired a new position in shares of Compass Pathways in the 4th quarter valued at $69,000. Institutional investors and hedge funds own 46.19% of the company’s stock.

Analyst Ratings Changes

CMPS has been the topic of a number of recent analyst reports. Morgan Stanley dropped their price objective on shares of Compass Pathways from $18.00 to $16.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 25th. Compass Point set a $15.00 price objective on shares of Compass Pathways in a research report on Thursday, February 12th. BTIG Research reissued a “buy” rating and issued a $14.00 price objective on shares of Compass Pathways in a research report on Monday. Royal Bank Of Canada increased their price objective on shares of Compass Pathways from $21.00 to $22.00 and gave the company an “outperform” rating in a research report on Wednesday, February 18th. Finally, HC Wainwright increased their price objective on shares of Compass Pathways from $40.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.63.

Compass Pathways Trading Up 42.0%

Shares of Compass Pathways stock opened at $9.46 on Tuesday. The company has a fifty day simple moving average of $6.43 and a 200-day simple moving average of $6.38. Compass Pathways has a 12-month low of $2.25 and a 12-month high of $10.21. The company has a current ratio of 0.77, a quick ratio of 0.77 and a debt-to-equity ratio of 0.55. The stock has a market cap of $1.22 billion, a price-to-earnings ratio of -3.06 and a beta of 2.01.

Compass Pathways (NASDAQ:CMPS) last issued its earnings results on Tuesday, March 24th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.59). On average, equities analysts forecast that Compass Pathways will post -1.68 EPS for the current fiscal year.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.